Education
About Us
Working with TipRanks
Follow Us
Quantum Biopharma Ltd. Subordinate Voting Shares Class B (QNTM)
:QNTM
QNTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.70 - $38.25
Previous CloseN/A
Volume44.35K
Average Volume (3M)133.68K
Market Cap
$60.70M
Enterprise Value$8.79M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 12, 2025EPS Estimate
-2.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares Outstanding3,815,835
10 Day Avg. Volume122,070
30 Day Avg. Volume133,682
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Quantum Biopharma News
QNTM FAQ
What was Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s price range in the past 12 months?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B lowest stock price was $2.70 and its highest was $38.25 in the past 12 months.
What is Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s market cap?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s market cap is $60.70M.
When is Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s upcoming earnings report date?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s upcoming earnings report date is Nov 12, 2025 which is in 45 days.
How were Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s earnings last quarter?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B released its earnings results on Aug 06, 2025. The company reported -$3.188 earnings per share for the quarter, missing the consensus estimate of -$0.166 by -$3.023.
Is Quantum Biopharma Ltd. Subordinate Voting Shares Class B overvalued?
According to Wall Street analysts Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s price is currently Overvalued.
Does Quantum Biopharma Ltd. Subordinate Voting Shares Class B pay dividends?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B does not currently pay dividends.
What is Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s EPS estimate?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s EPS estimate is -2.66.
How many shares outstanding does Quantum Biopharma Ltd. Subordinate Voting Shares Class B have?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B has 3,815,835 shares outstanding.
What happened to Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s price movement after its last earnings report?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B reported an EPS of -$3.188 in its last earnings report, missing expectations of -$0.166. Following the earnings report the stock price went down -0.497%.
Which hedge fund is a major shareholder of Quantum Biopharma Ltd. Subordinate Voting Shares Class B?
Currently, no hedge funds are holding shares in QNTM
Quantum Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $34.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
334.04%
12-Months-Change
Fundamentals
Return on Equity
-235.05%
Trailing 12-Months
Asset Growth
-3.66%
Trailing 12-Months
Company Description
Quantum Biopharma Ltd. Subordinate Voting Shares Class B
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
Technical Analysis
Ownership Overview
24.30% Insiders
1.41% Other Institutional Investors
73.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---